Barclays
http://www.barclays.com/Barclays plc is a global financial services provider engaged in retail and commercial banking, credit cards, investment banking, wealth management and investment management services. It has an extensive international presence in Europe, the United States, Africa and Asia. In addition, the bank is one of the ten largest banks in the world measured by market capitalization. Barclays is headquartered in London, England.
-
Stocks Crossing 50-Day SMA 12/12: (TSL) (XOM) JOY) Above; (TEVA) (KOG) (TLT) Below
-
Barclays on U.S. Specialty Pharmaceuticals: Muddling Now, but Opportunity Remains
-
Barclays Maintains an 'Equalweight' on Teva Pharma (TEVA); Adjusting Estimates After Business Update
-
Barclays on Healthcare: Top Takeaways from our Second Annual Therapeutics Symposium
-
Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments on MYL, PRX, TEVA, & WCRX
-
Notable Analyst Rating Changes 03/15: (AMD) (UNP) (LVLT) Upgraded; (EBAY) (LAZ) (WMS) Downgraded
-
Unusual 11 Midday Movers 02/15: (BPAX) (EGY) (THLD) Higher; (ZNGA) (PWAV) (IPSU) Lower
-
Morning Movers 02/15: (BPAX) (EGY) (IPAS) (CBK) Higher; (VG) (ZNGA) (ACPW) Lower
-
Barclays Initiating Coverage: A Seamless Approach to Biopharmaceuticals
-
Notable Analyst Rating Changes 11/08: (MFA) (EMR) (STJ) Upgraded; (ALU) (RIMM) (PXD) Downgraded
-
Notable Analyst Rating Changes 11/03: (TEVA) (ARO) (OPEN) Upgraded; (DNDN) (DXCM) (NLY) Downgraded
-
Notable Analyst Rating Changes 10/24: (BHP) (XL) (USU) Upgraded; (WEN) (IFF) (TEVA) Downgraded
-
Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
-
Barclays on Global Pharmaceuticals: Global Therapeutic Conference Preview: Multiple Sclerosis
-
Notable Analyst Rating Changes 05/09: (BHI) (ETFC) (PEP) Upgraded; (SPLS) (MJN) (DRWI) Downgraded
-
Notable 52-Week Highs and Lows of the Day 04/21: (SIRI) (UNH) (BIIB) High; (TEVA) (ZSTN) (AMR) Low
-
Notable Analyst Rating Changes 04/19: (ZION) (NAV) (RBN) Upgraded; (GS) (ABAT) (CRU) Downgraded
-
Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); Detailed Laquinimod Results Support Our Positive View
-
Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); P&G Partnership Has Multiple Benefits
-
Barclays on U.S. Specialty Pharmaceuticals: Mylan Influencing Lipitor Landscape?
-
Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); Takeaways from HC Conference Events
-
Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); First-Time FY11 Guidance Tomorrow a Key Focus
-
Teva Pharma (TEVA) Enters $1.5B Revolving Credit Facility
-
Barclays Reiterates an 'Overweight' on Teva Pharmaceutical (TEVA); Stock Lull Creates Opportunity
-
Notable Analyst Rating Changes 07/26: AONE, PTEN, WFR, BX Upgraded; SAFM, TEVA, SLB, STM Downgraded
-
Barclays on Specialty Pharmaceuticals: June Qtr Preview for Selected Companies
-
Notable Analyst Rating Changes 06/24: PNW, HRP, BBBY, WYNN Upgraded; LOW, WTNY, HD, TRW Downgraded
-
Notable Analyst Rating Changes 12/07: POT, BRCD, SPWRA, STP, JASO, AXP Upgraded; MMC, ABX, ALTH, AVP, ZLC Downgraded
-
David Moenning's Daily State of the Markets: 3/13
-
Top 15 For 2008 (No. 14): M&A Wreckage
-
Pre-Open Movers 6/16: XM/Sirius (XMSR, SIRI) Up on Expected FCC Merger Approval; ACADIA (ACAD) Sinks As Drug Fails
